Objective: The aim of this study was to describe a rapid retreatment strate
gy in patients with paclitaxel hypersensitivity reactions.
Methods: A retrospective review of all patients receiving standard S-hour i
nfusion paclitaxel-based chemotherapy after proper premedication at the Dep
artment of Gynecologic Oncology, University of Bari between 1995 and 1998,
was performed. All patients who developed hypersensitivity reactions to pac
litaxel were identified and their treatment course and outcome were reviewe
d. A review of the literature on this subject is also presented.
Results: Eighty-six women were treated with 461 cycles of paclitaxel-based
chemotherapy at our Unit. Twelve patients (14%) developed hypersensitivity
reactions. All had received standard premedication consisting of corticoste
roids and hystamine blockers. Hypersensitivity reactions consisted of isola
ted face flushes (3 patients), dyspnea and chest tightness (4 patients) or
bronchospasm (5 patients). Eleven patients were rechallenged with the origi
nal paclitaxel solution starting at a slower rate after a second premedicat
ion with a double dosage of steroids. None of these patients had reactions
in subsequent courses. Only one patient (the first of this series treated i
n February 1995), was retreated 5 days later under strict monitoring in int
ensive care unit.
Conclusions: Retreatment with the original paclitaxel solution is safe in a
lmost all patients with hypersensitivity reactions, The drug should be admi
nistered within the next 24 hours with a new premedication protocol.